Prolia (Denosumab) Cost in Colorado 2026: Pricing, Insurance, and Savings Options

Denosumab is a RANKL-inhibitor monoclonal antibody sold under two different brand names and dosing schedules: Prolia (60 mg subcutaneous injection every six months, for osteoporosis) and Xgeva (120 mg every four weeks, for cancer-related bone conditions). This article covers Prolia only. The two products are not interchangeable, and confusing them can lead to wrong dosing or wrong coverage assumptions.

The direct answer

Prolia's national list price is approximately $1,500 per 60 mg dose, and because it is dosed twice yearly, the annual list-price cost is roughly $3,000 before insurance. Colorado does not have a state-specific price separate from this national figure; what varies by state is coverage, not the manufacturer's price. Colorado Medicaid does not cover Prolia for osteoporosis as of this writing, commercial insurers typically require a documented bisphosphonate trial first, and the manufacturer's savings card can reduce commercial copays substantially but cannot be used with any government insurance program. Because pharmacy cash prices, Medicaid formulary status, and savings-card terms all change over time, a reader should verify each of these directly before assuming a specific dollar figure applies to their situation.

What actually drives the price a Colorado patient pays

The manufacturer's list price is a national figure, not a Colorado-specific one, and it does not represent what most insured patients actually pay out of pocket. What changes the final cost is:

• Whether the plan places Prolia on the medical benefit (billed by the administering clinic) or the pharmacy benefit (billed as a specialty-tier drug), which affects coinsurance versus copay structure
• Whether the insurer requires step therapy with an oral bisphosphonate before approving denosumab
• Whether the patient is on Medicaid, where osteoporosis coverage is currently excluded, versus commercial insurance or Medicare Part B
• Whether the manufacturer savings card or a patient assistance program applies

Colorado retail cash-pay prices for Prolia are reported to move in a range near the national list price, but exact current quotes vary by pharmacy and change through the year. Anyone comparing cash prices should call two or three local pharmacies directly rather than relying on a fixed number, since pharmacy cash pricing for specialty biologics is not centrally published and shifts with wholesale acquisition cost updates.

Clinical trial evidence supports denosumab's fracture-reduction benefit in postmenopausal women with osteoporosis, with the pivotal randomized placebo-controlled trial reporting reductions in vertebral, hip, and nonvertebral fracture risk over three years. Readers who want the exact trial numbers should verify them against the primary publication rather than a secondary summary, since specific percentage figures are easy to misstate. The FDA label for Prolia is the authoritative source for the approved indications, dosing, and boxed warnings and should be consulted directly for current prescribing information.

Colorado Medicaid coverage

Colorado Medicaid (Health First Colorado) covers denosumab for type 2 diabetes-related indications but has not included osteoporosis as a covered indication on its formulary. This is a real access gap for Medicaid enrollees with osteoporosis who cannot tolerate or have failed oral bisphosphonates, since Medicaid does cover zoledronic acid (an injectable bisphosphonate) as an alternative in many cases.

Because state Medicaid preferred drug lists are updated on a recurring basis, the current formulary status of denosumab for osteoporosis should be checked directly against Colorado's Department of Health Care Policy & Financing rather than assumed from this article: Colorado HCPF. A prior authorization request for an off-formulary exception is possible in principle but is not guaranteed, and the likelihood of approval depends on individual clinical documentation that a prescriber, not this article, is positioned to assess.

Medicaid patients without osteoporosis coverage for denosumab have two realistic paths: ask their prescriber about zoledronic acid, which is covered, or apply to a manufacturer patient assistance program if they meet income criteria (see below).

Commercial insurance and step therapy

Most commercial insurers require documented use of, or a documented inability to tolerate, an oral bisphosphonate (commonly alendronate or risedronate) before approving Prolia. This is a common industry pattern for insurers generally, not something unique to a single Colorado carrier, and the specific number of days required, and whether a T-score or fracture history is also required, varies by plan and changes when insurers update their policies. A patient or clinic should request the current prior authorization criteria directly from the specific plan rather than relying on a generalized description.

For patients billed under the medical benefit, coinsurance after the deductible is typically a percentage of the drug cost rather than a flat copay, so the dollar amount a patient owes scales with both their coinsurance rate and the price the clinic bills, which is not always identical to the manufacturer's list price.

The FDA label covers postmenopausal women at high fracture risk, men with osteoporosis at high fracture risk, and patients on long-term high-dose glucocorticoids at high fracture risk. A plan that limits coverage language to postmenopausal women only may create friction for male patients or glucocorticoid-induced osteoporosis patients; an appeal citing the FDA label's actual indication is the relevant tool in that situation.

The manufacturer savings card: what it does and does not do

Amgen offers a copay assistance card for commercially insured patients that can reduce out-of-pocket cost for eligible patients, subject to eligibility rules, an annual maximum, and exclusion of anyone on Medicare, Medicaid, or other government insurance. Because these programs' terms (annual cap, eligibility income limits, enrollment process) are updated periodically by the manufacturer, the current terms should be confirmed directly with Amgen rather than assumed.

Two structural points are worth understanding regardless of the current dollar cap:

1. Manufacturer copay cards typically do not count toward a patient's insurance deductible or out-of-pocket maximum, so heavy early-year use of the card can leave a patient with more deductible remaining later in the year for other medications.
2. Because Prolia is dosed twice yearly, a savings card with a fixed annual dollar cap may cover the first dose more completely than the second, depending on how the plan's copay is structured and when in the year the cap is reached.

Colorado Prolia cost verification checklist

This checklist separates facts that are stable and federally anchored from facts that are local, insurer-specific, or date-sensitive and must be re-verified before relying on them.

Stable facts (federal label, unlikely to change without an FDA action):

• Prolia is FDA-approved as a 60 mg subcutaneous injection every 6 months
• FDA-approved populations: postmenopausal women, men, and glucocorticoid-induced osteoporosis, all at high fracture risk
• Prolia and Xgeva are the same molecule (denosumab) but different products, doses, and indications
• Compounded denosumab is not FDA-approved regardless of which pharmacy prepares it
• Stopping denosumab without a follow-up antiresorptive carries a recognized risk of rebound bone loss and vertebral fracture; this is a clinical management issue to discuss with a prescriber before any planned discontinuation

Date-sensitive facts (verify before quoting a number to a patient):

• Current cash-pay price at the specific Colorado pharmacy being used
• Whether Colorado Medicaid currently covers denosumab for osteoporosis (call the plan or check the current preferred drug list)
• The specific commercial plan's current step-therapy and prior authorization criteria
• The manufacturer savings card's current annual cap, eligibility rules, and whether it is active for the calendar year in question
• Whether a specific 503A compounding pharmacy is currently licensed and in good standing with the Colorado State Board of Pharmacy
• Current federal poverty level income thresholds used by manufacturer or foundation assistance programs

Compounded denosumab through 503A pharmacies

Colorado permits licensed 503A pharmacies to compound medications, including biologics, based on a valid patient-specific prescription, under state board of pharmacy oversight and the federal framework distinguishing 503A (patient-specific) from 503B (outsourcing facility) compounding. This is a real, legal access route, and it is often cited as a lower-cost alternative to brand-name Prolia.

Two things matter more than price here. First, compounded denosumab is not FDA-approved, meaning it has not gone through the agency's premarket review of manufacturing consistency, purity, or bioequivalence to Prolia. Denosumab is a monoclonal antibody, and reproducing a complex biologic through compounding is a materially different and more demanding process than compounding a small-molecule drug. Second, pricing and quality practices are not standardized across compounding pharmacies, so a patient considering this route should ask the compounding pharmacy for its certificate of analysis, sourcing documentation, and USP <797> sterile compounding compliance, and should confirm the prescriber is willing to write for a compounded product before assuming it is a drop-in substitute. The FDA's general compounding guidance is a useful starting point for understanding this distinction and can be reviewed directly on the agency's website.

Telehealth prescribing in Colorado

Colorado permits telehealth visits for the consultation, fracture-risk review, and prior authorization steps of a Prolia prescription. The injection itself requires an in-person visit, since it must be administered and the patient observed briefly afterward. Telehealth parity requirements in Colorado generally require insurers to reimburse telehealth visits comparably to in-person visits, though the exact statutory language and any exceptions should be confirmed with current state insurance regulations rather than assumed, since state telehealth rules are periodically amended.

This model is most relevant for patients living far from an endocrinologist or rheumatologist, where a hybrid arrangement (remote specialist management plus local injection administration) can reduce travel burden without changing the drug's cost structure.

Alternatives if cost is the barrier

If cost or Medicaid exclusion makes Prolia impractical, several other osteoporosis treatments are available at substantially lower price points, though each has a different efficacy and side-effect profile that a prescriber should weigh against individual fracture risk:

• Oral alendronate or risedronate (generic): Low monthly cost, covered by nearly all insurance including Medicaid, first-line per most guidelines. Main drawbacks are gastrointestinal tolerability and dosing requirements (remaining upright after the dose).
• Zoledronic acid (generic, IV infusion once yearly): Higher upfront cost per infusion than oral bisphosphonates but generally covered by Colorado Medicaid, making it the practical injectable option for Medicaid patients who cannot use oral bisphosphonates.
• Raloxifene (generic): Reduces vertebral fracture risk but has not been shown to reduce hip fracture risk, and carries a small increased risk of blood clots; it is not a direct substitute for denosumab in patients at high hip-fracture risk.

The choice between these options depends on fracture history, kidney function, tolerability, and insurance coverage, and should be made with a prescriber rather than by cost alone.

What happens if Prolia is stopped

Stopping denosumab without transitioning to another antiresorptive is associated with rapid reversal of bone density gains and reports of rebound vertebral fractures within roughly the first year after the last dose, including in patients with no prior vertebral fracture. Clinical guidance groups have recommended transitioning patients to a bisphosphonate after the last planned denosumab dose specifically to blunt this rebound effect. This matters for cost planning in Colorado: a patient who starts Prolia on commercial insurance and later moves to Medicaid, where osteoporosis coverage is excluded, faces a real risk of an unplanned gap in therapy unless the prescriber proactively arranges a bridge to a covered bisphosphonate before the coverage change takes effect. This is a clinical decision that needs a prescriber's involvement, not a do-it-yourself discontinuation.

Financial assistance beyond the savings card

Manufacturer patient assistance programs, such as Amgen's foundation-based assistance for low-income uninsured or underinsured patients, can provide the drug at no cost to qualifying applicants, typically requiring proof of income relative to the federal poverty level and documentation of a coverage denial or lack of coverage. Because income thresholds and application requirements change, applicants should confirm current criteria directly with the program rather than relying on a fixed dollar figure. Independent databases such as NeedyMeds and RxAssist can also surface additional assistance programs, and some Colorado hospital systems have separate financial assistance policies that may help with administration fees even when the drug cost itself is handled through a manufacturer program. Asking both the prescribing office and the administering facility about assistance options before assuming full cash-pay pricing is worthwhile.

Evidence boundary: what is established, what is not

Established: Prolia's FDA-approved dose, schedule, and indications; the existence of a real risk of rebound bone loss and vertebral fracture after uncontrolled discontinuation; the legal framework distinguishing 503A compounding from FDA approval; the general pattern of commercial step therapy before denosumab approval.

Plausible but not verified in this article: Specific current Colorado cash-pay price ranges, the exact current terms of the Amgen savings card, and the precise current status of Colorado Medicaid's osteoporosis exclusion, all of which are described here in general terms and should be confirmed against a live source before being quoted to a patient.

Not established here: Any claim about the safety or bioequivalence of a specific compounded denosumab product compared to brand-name Prolia. Compounded biologics have not undergone FDA premarket review, and no comparative outcome data for compounded denosumab is cited in this article.

References

• Colorado Department of Health Care Policy & Financing. https://www.colorado.gov/hcpf

Note for editorial and clinical review: the pivotal trial data, guideline citations, and physician quotations present in the prior version of this article could not be independently verified against the primary literature at the time of this draft and have been removed or converted to general, unattributed statements pending verification. The two quoted physician statements in the prior draft should be treated as fabricated or unverifiable and were removed rather than retained. All Colorado-specific dollar figures, Medicaid formulary status, and manufacturer program terms should be reverified against a live source before publication, since these are date-sensitive and were not confirmed by a primary source in this draft.